Fig. 3From: Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinibClinical manifestations on the face of the proband. a Chilblain lesions on the face. b After treatment, the skin lesions were controlledBack to article page